Access the full text.
Sign up today, get DeepDyve free for 14 days.
Hua-wen Sun, Chong Wu, Hai-yan Tan, Qiu-shuang Wang (2011)
Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.Hepato-gastroenterology, 59 115
Michiro Susa, A. Iyer, Keinosuke Ryu, E. Choy, F. Hornicek, H. Mankin, L. Milane, M. Amiji, Z. Duan (2010)
Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in OsteosarcomaPLoS ONE, 5
J. Fletcher, M. Haber, M. Henderson, M. Norris (2010)
ABC transporters in cancer: more than just drug efflux pumpsNature Reviews Cancer, 10
Sampath Abeylath, M. Amiji (2011)
'Click' synthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeutics.Bioorganic & medicinal chemistry, 19 21
D. Lamendola, Z. Duan, R. Yusuf, M. Seiden (2003)
Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.Cancer research, 63 9
Cancer Res, 46
P. Valk, C. Kalken, H. Ketelaars, H. Broxterman, G. Scheffer, C. Kuiper, T. Tsuruo, J. Lankelma, C. Meijer, H. Pinedo, R. Scheper (1990)
Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissue
S. Kaye (2008)
Reversal of drug resistance in ovarian cancer: where do we go from here?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 16
Meghna Talekar, J. Kendall, W. Denny, S. Garg (2011)
Targeting of nanoparticles in cancer: drug delivery and diagnosticsAnti-Cancer Drugs, 22
J. Gillet, M. Gottesman (2010)
Mechanisms of multidrug resistance in cancer.Methods in molecular biology, 596
Ann Oncol, 1
H. Maeda (2001)
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.Advances in enzyme regulation, 41
C. Schwartz, R. Gorlick, L. Teot, M. Krailo, Zhengjia Chen, A. Goorin, H. Grier, M. Bernstein, P. Meyers (2007)
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 15
M. Willingham, M. Cornwell, C. Cardarelli, M. Gottesman, I. Pastan (1986)
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.Cancer research, 46 11
G. Schuurhuis, H. Broxterman, A. Cervantes, Th. Heijningen, J. Lange, Jan Baak, H. Pinedo, J. Lankelma (1989)
Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.Journal of the National Cancer Institute, 81 24
Michiro Susa, A. Iyer, Keinosuke Ryu, F. Hornicek, H. Mankin, M. Amiji, Z. Duan (2009)
Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcomaBMC Cancer, 9
D. Belpomme, S. Gauthier, E. Pujade-Lauraine, T. Facchini, M. Goudier, I. Krakowski, G. Netter-Pinon, M. Frénay, C. Gousset, F. Marie, M. Benmiloud, F. Sturtz (2000)
Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 11 11
H. Devalapally, Z. Duan, M. Seiden, M. Amiji (2008)
Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric NanoparticlesClinical Cancer Research, 14
S. Bielack, B. Kempf‐Bielack, G. Delling, G. Exner, S. Flege, K. Helmke, R. Kotz, M. Salzer‐Kuntschik, M. Werner, W. Winkelmann, A. Zoubek, H. Jürgens, K. Winkler (2002)
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 3
Alex Chen, Min Zhang, Dongguang Wei, D. Stueber, O. Taratula, T. Minko, Huixin He (2009)
Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.Small, 5 23
Clin Adv Hematol Oncol, 8
C. Nieth, Axel Priebsch, Alexandra Stege, H. Lage (2003)
Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)FEBS Letters, 545
D. Northfelt, F. Martin, P. Working, P. Volberding, Julie Russell, M. Newman, M. Amantea, L. Kaplan (1996)
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 36
Z. Duan, Katherine Brakora, M. Seiden (2004)
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.Molecular cancer therapeutics, 3 7
F. Hornicek, M. Gebhardt, M. Wolfe, F. Kharrazi, H. Takeshita, Selene Parekh, D. Zurakowski, H. Mankin (2000)
P-Glycoprotein Levels Predict Poor Outcome in Patients With OsteosarcomaClinical Orthopaedics and Related Research, &NA;
MARIE¨LLE Smeets, R. Raymakers, G. Vierwinden, A. Pennings, L. Locht, H. Wessels, J. Boezeman, T. Witte (1997)
A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicityBritish Journal of Haematology, 96
J. Kolitz, S. George, R. Dodge, D. Hurd, B. Powell, S. Allen, E. Vélez‐garcía, J. Moore, T. Shea, E. Hoke, M. Caligiuri, J. Vardiman, C. Bloomfield, R. Larson (2004)
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 21
Cancer Res, 47
Maha Saad, O. Garbuzenko, T. Minko (2008)
Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.Nanomedicine, 3 6
P Valk, CK Kalken, H Ketelaars, HJ Broxterman, G Scheffer, CM Kuiper, T Tsuruo, J Lankelma, CJ Meijer, HM Pinedo (1990)
Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues: analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein moleculeAnn Oncol., 1
HG Keizer, GJ Schuurhuis, HJ Broxterman, J Lankelma, WG Schoonen, J Rijn, HM Pinedo, H Joenje (1989)
Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cellsCancer Res., 49
C. Pecot, G. Calin, R. Coleman, G. Lopez-Berestein, A. Sood (2011)
RNA interference in the clinic: challenges and future directionsNature Reviews Cancer, 11
Hyo-Kyung Han (2011)
Role of transporters in drug interactionsArchives of Pharmacal Research, 34
Tamara Minko, P. Kopečková, V. Pozharov, J. Kopeček (1998)
HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.Journal of controlled release : official journal of the Controlled Release Society, 54 2
P. Chaudhary, I. Roninson (1991)
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cellsCell, 66
Cancer Res, 48
R. Agarwal, S. Kaye (2003)
Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 3
J. Whelan, R. Jinks, A. McTiernan, M. Sydes, James Hook, L. Trani, B. Uscinska, V. Bramwell, I. Lewis, M. Nooij, M. Glabbeke, R. Grimer, P. Hogendoorn, A. Taminiau, H. Gelderblom (2012)
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.Annals of oncology : official journal of the European Society for Medical Oncology, 23 6
Cancer Res, 49
M. Bhavsar, M. Amiji (2007)
Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS).Journal of controlled release : official journal of the Controlled Release Society, 119 3
A. Hindenburg, M. Baker, E. Gleyzer, V. Stewart, N. Case, R. Taub (1987)
Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance.Cancer research, 47 5
A. Iyer, G. Khaled, Jun Fang, H. Maeda (2006)
Exploiting the enhanced permeability and retention effect for tumor targeting.Drug discovery today, 11 17-18
J Clin Oncol, 18
L. Vlerken, Tushar Vyas, M. Amiji (2007)
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular DeliveryPharmaceutical Research, 24
C. Riganti, C. Voena, J. Kopecka, P. Corsetto, G. Montorfano, Emanuele Enrico, C. Costamagna, A. Rizzo, D. Ghigo, A. Bosìa (2011)
Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.Molecular pharmaceutics, 8 3
Li Zheng, Jia-qiang Ren, Hua Li, Zhaolu Kong, Hong-guang Zhu (2004)
Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapyCell Research, 14
Rita Kandel, Sue Campbell, Sandra Noble-Topham, Robert Bell, I Andrulis (1995)
Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study.Diagnostic molecular pathology : the American journal of surgical pathology, part B, 4 1
Cancer Res, 63
K. Dillen, J. Vandervoort, G. Mooter, A. Ludwig (2006)
Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.International journal of pharmaceutics, 314 1
L. Milane, Z. Duan, M. Amiji (2011)
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.Molecular pharmaceutics, 8 1
P. Sonneveld, S. Suciu, P. Weijermans, M. Beksaç, R. Neuwirtová, G. Solbu, Lokhorst Hm, J. Lelie, H. Dōhner, H. Gerhartz, C. Segeren, R. Willemze, B. Lowenberg (2001)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914)British Journal of Haematology, 115
G. Ferrandina, G. Corrado, A. Licameli, D. Lorusso, Gilda Fuoco, S. Pisconti, G. Scambia (2010)
Pegylated liposomal doxorubicin in the management of ovarian cancerTherapeutics and Clinical Risk Management, 6
A. Poveda, A. López-pousa, J. Martín, J. Muro, R. Bernabé, A. Casado, C. Balañà, O. Sanmartín, M. Menéndez, P. Escudero, J. Cruz, E. Belyakova, D. Menéndez, J. Buesa (2005)
Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)Sarcoma, 9
W. Klimecki, B. Futscher, T. Grogan, W. Dalton (1994)
P-glycoprotein expression and function in circulating blood cells from normal volunteers.Blood, 83 9
Alina Shapira, Y. Livney, H. Broxterman, Y. Assaraf (2011)
Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 14 3
V. Torchilin (2005)
Recent advances with liposomes as pharmaceutical carriersNature Reviews Drug Discovery, 4
B. Sikic (1997)
Pharmacologic approaches to reversing multidrug resistance.Seminars in hematology, 34 4 Suppl 5
D. O’Malley, D. Richardson, Patrick Rheaume, R. Salani, E. Eisenhauer, G. McCann, J. Fowler, L. Copeland, D. Cohn, F. Backes (2011)
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.Gynecologic oncology, 121 2
T. Licht, I. Pastan, Michael Gottesman, François Herrmann (1994)
P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cellsAnnals of Hematology, 69
I. Sugawara, Iyo Kataoka, Y. Morishita, H. Hamada, T. Tsuruo, S. Itoyama, S. Mori (1988)
Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.Cancer research, 48 7
SD Shnyder, AJ Hayes, J. Pringle, CW Archer (1998)
P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.British Journal of Cancer, 78
J. MacDiarmid, Nancy Amaro-Mugridge, Jocelyn Madrid-Weiss, I. Sedliarou, S. Wetzel, Kartini Kochar, Vatsala Brahmbhatt, Leo Phillips, Scott Pattison, C. Petti, B. Stillman, R. Graham, H. Brahmbhatt (2009)
Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drugNature Biotechnology, 27
K. Uhrich, S. Cannizzaro, R. Langer, K. Shakesheff (1999)
Polymeric systems for controlled drug release.Chemical reviews, 99 11
D. Geller, R. Gorlick (2010)
Osteosarcoma: a review of diagnosis, management, and treatment strategies.Clinical advances in hematology & oncology : H&O, 8 10
Mol Cancer Ther, 3
Hepatogastroenterology, 59
Lilian Vlerken, Z. Duan, M. Seiden, M. Amiji (2007)
Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.Cancer research, 67 10
Huan Meng, M. Liong, T. Xia, Zongxi Li, Zhaoxia Ji, J. Zink, A. Nel (2010)
Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.ACS nano, 4 8
H. Keizer, G. Schuurhuis, H. Broxterman, J. Lankelma, W. Schoonen, J. Rijn, H. Pinedo, H. Joenje (1989)
Correlation of multidrug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cellsCancer Research, 49
J. Wunder, Shelley Bull, Vicky Aneliunas, Peter Lee, Aileen Davis, Chris Beauchamp, Ernest Conrad, R. Grimer, John Healey, Michael Rock, R. Bell, I. Andrulis (2000)
MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 14
N. Baldini, K. Scotlandi, G. Barbanti-Bròdano, M. Manara, D. Maurici, G. Bacci, F. Bertoni, P. Picci, S. Sottili, M. Campanacci, M. Serra (1995)
Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.The New England journal of medicine, 333 21
Biocompatible dextran-based nanoparticles that are directly translatable to clinical medicine may lead to new potential therapeutics for reversing MDR in patients with cancer.
Clinical Orthopaedics and Related Research – Wolters Kluwer Health
Published: Sep 21, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.